key: cord-0871571-zzui1qfg
authors: Theiler, Regan N.; Wick, Myra; Mehta, Ramila; Weaver, Amy L.; Virk, Abinash; Swift, Melanie
title: Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy
date: 2021-08-20
journal: Am J Obstet Gynecol MFM
DOI: 10.1016/j.ajogmf.2021.100467
sha: ef341d91eab0316908dd89cc0d2940a8d941c72c
doc_id: 871571
cord_uid: zzui1qfg

BACKGROUND: : SARS-CoV-2 infection during pregnancy is associated with significant maternal morbidity and increased rates of preterm birth. For this reason, COVID-19 vaccine administration in pregnancy has been endorsed by multiple professional societies including ACOG and SMFM despite exclusion of pregnant women from initial clinical trials of vaccine safety and efficacy. However, to date little data exists regarding outcomes after COVID-19 vaccination of pregnant patients. STUDY DESIGN: : A comprehensive vaccine registry was combined with a delivery database for an integrated healthcare system to create a delivery cohort including vaccinated patients. Maternal sociodemographic data were examined to identify factors associated with COVID-19 vaccination. Pregnancy and birth outcomes were analyzed, including a composite measure of maternal and neonatal pregnancy complications, the Adverse Outcome Index. RESULTS: : Of 2002 patients in the delivery cohort, 140 (7.0%) received a COVID-19 vaccination during pregnancy and 212 (10.6%) experienced a COVID-19 infection during pregnancy. The median gestational age at first vaccination was 32 weeks (range 13 6/7-40 4/7), and patients vaccinated during pregnancy were less likely than unvaccinated patients to experience COVID-19 infection prior to delivery (1.4% (2/140) vs. 11.3% (210/1862), P<0.001). No maternal COVID-19 infections occurred after vaccination during pregnancy. Factors significantly associated with increased likelihood of vaccination in a multivariable logistic regression model included older age, higher level of maternal education, being a non-smoker, use of infertility treatment for the current pregnancy, and lower gravidity. No significant difference in the composite adverse outcome (5.0% (7/140) vs. 4.9% (91/1862), P=0.95) or other maternal or neonatal complications, including thromboembolic events and preterm birth, was observed in vaccinated compared to unvaccinated patients. CONCLUSIONS: : Vaccinated pregnant women in this birth cohort were less likely to experience COVID-19 infection compared to unvaccinated pregnant patients, and COVID-19 vaccination during pregnancy was not associated with increased pregnancy or delivery complications. The cohort was skewed toward late pregnancy vaccination, and thus findings may not be generalizable to vaccination during early pregnancy.

In late 2020, the United States Food and Drug Administration (FDA) approved two mRNA vaccines, manufactured by Pfizer-BioNTech (BNT162b2) (Pfizer, Inc; Philadelphia, Pennsylvania) and Moderna (mRNA-1273) (ModernaTX, Inc; Cambridge, Massachusetts), for emergency use to prevent COVID-19 illness. Both vaccines were studied in large numbers of subjects during phase 3 randomized controlled trials, and both were shown to be highly effective at preventing COVID-19 infection in non-pregnant participants.. 1, 2 Because none of the trials undertaken to gain FDA approval included pregnant or lactating women, use of the vaccines during pregnancy and lactation has been controversial. 3 During phase 1A of the vaccine rollout in the U.S., healthcare workers were the first population with access to vaccination, and thus many pregnant healthcare workers received the vaccine. During phase 1B, teachers and other essential workers were vaccinated, adding to the population of reproductive age who were eligible for vaccination. Starting in December 2020, recommendations from the American COVID-19 disease during pregnancy is known to have severe manifestations in pregnant women compared to non-pregnant controls, with increased risk for maternal hospitalization, ICU admission, invasive ventilation, and death [5] [6] [7] . Other adverse outcomes observed with SARS-CoV-2 infection during pregnancy include increased rates of preterm birth and increased preeclampsia incidence, both of which have been linked to inflammatory mechanisms 8 . Because of the known increased maternal risk of adverse outcomes with COVID-19 infection and the lack of proven harm from the available vaccines, many patients have opted for vaccination despite limited safety and efficacy data for the vaccines in pregnant patients 9 . The vaccines are thought to be effective when administered during pregnancy, as antibody production occurs rapidly after administration. However, immune alterations that occur in pregnancy may theoretically decrease the vigor of cell-mediated immune responses to infection. 2, 10 Neutralizing antibody response is highly reassuring and suggests robust efficacy during pregnancy with possible benefit to the neonate.

Recently published COVID-19 vaccine surveillance data from the Centers for Disease Control and Prevention's (CDC) voluntary V-SAFE registry including 3958 subjects vaccinated during pregnancy suggests that pregnant women do not have increased rates of adverse vaccine reactions compared to control patients, and that patients do not report increases in adverse pregnancy outcomes compared to non-pregnant women 11 . The V-SAFE data, however, are limited to patient-reported vaccine reactions and pregnancy events; conclusions are thus subject to selection bias and lack of validated primary data supporting conclusions. For this reason, vaccine efficacy should be demonstrated in pregnancy using infectious outcomes as well. Adding to the available data, we present pregnancy outcomes from a Mayo Clinic Health System delivery cohort delivering during the first four months of vaccine availability. The composite outcome, the adverse outcome index (AOI) was calculated as a composite of any of the following events during the delivery hospitalization: a) maternal death during hospitalization, b) intrapartum neonatal death within 7 days of birth with birthweight ≥ 2500g and ≥37 weeks gestation, c) hypoxic ischemic encephalopathy, d) uterine rupture, e) unplanned maternal ICU admission, f) return to the operating room within 72 hours of delivery, g) postpartum hemorrhage with blood transfusion, h) third or fourth degree laceration, i) five minute Apgar <7 with birthweight ≥2500g and ≥37 weeks gestation, j) admission to the NICU within 1 day of birth for >1 day with birthweight ≥2500g and ≥37 weeks gestation, or k) neonatal birth trauma. All qualifying events were verified by chart review. The AOI for a group of patients was calculated as the number of patients with one or more identified adverse events divided by the total number of deliveries, multiped by 100. A woman with multiple gestations was counted as a single delivery. A modified AOI was also calculated by not considering third-and fourthdegree perineal laceration as an adverse event. Additional outcomes measured included thromboembolism or stroke within 4 weeks before or after delivery, gestational hypertensive disorders diagnosed up to 72 hours after delivery, low and very low birth weight, preterm birth (< 37 weeks gestation), length of postpartum maternal stay after delivery, and stillbirth.

The primary outcome in this study was AOI. [12] [13] [14] The AOI was 4.9% within the Mayo Clinic

Health System for calendar year 2019. This study was designed with 80% power, using a twosided chi-square test with a type I error rate of 0.05, to detect a difference in AOI of 4.9% vs. at least 11.5% between those without versus with a COVID-19 vaccine during pregnancy, based on 1862 and 140 patients in the two groups.

Data management and statistical analysis was performed using SAS version 9.4 (SAS institute, Cary, NC, USA). Comparisons between groups were evaluated using the chi-square test or Fisher's exact test for non-ordered categorical variables, the Wilcoxon rank sum test for ordinal variables, and the two-sample t-test for continuous variables. A multivariable logistic regression model was fit to identify a set of characteristics independently associated with having received a COVID-19 vaccine during pregnancy, by including all of the factors identified with p<0.20 based on univariate analysis. Prior to fitting the multivariable model an additional category was created for each variable with missing data. A 95% confidence interval (CI) for the difference in the AOI between two groups was calculated based on exact methods for a binomial parameter. All calculated p-values were two-sided and p-values less than 0.05 were considered statistically significant. Table A1 ). The median estimated gestational age (EGA) at initiation of the Table 2) . The composite pregnancy outcome, AOI, did not differ by maternal vaccination status, with rates of 5.0% (7/140) vs. 4.9% (91/1862) in the vaccinated and unvaccinated groups (95% CI for difference in proportions, -3.6% to 3.6%). No maternal or early neonatal deaths occurred in the cohort. Mode of delivery, gestational age at delivery, neonatal birth weight, thromboembolic events, and rates of gestational hypertension and pre-eclampsia also did not significantly differ between groups. Additional comparison between COVID-19 infected, nonvaccinated patients (n=210) and vaccinated patients without a history of COVID-19 infection (n=138) did not show any difference among the pregnancy outcomes examined in the cohort, but the study was not sufficiently powered to detect a difference in these outcomes (Appendix Table A2 ). Among the unvaccinated patients, pregnancy and birth outcomes did not significantly differ between those with (n=210) versus without (n=1652) a COVID-19 infection during pregnancy (Appendix Table A2 ). forward. This study reveals sociodemographic factors associated with vaccine access and/or uptake in the pregnant population. Vaccination eligibility during the timeframe analyzed was limited to healthcare workers, the elderly, and teachers or other essential workers. For this reason, we cannot discern whether sociodemographic differences in vaccination status are due to vaccine hesitancy or differences in eligibility for vaccination, but we do observe socioeconomic disparity between those who received vaccination during gestation and those who did not.

RESEARCH IMPLICATIONS: The current study largely represents outcomes after third trimester vaccination, but patients who received the vaccine during the late first through second trimesters and delivered preterm are also represented in this data set. The absence of an increase in preterm births in the cohort thus suggests that vaccination is unlikely to increase preterm birth rates, but analysis of outcomes from currently ongoing pregnancies will be needed to confirm this finding. Additional studies will be needed to examine differences in rare adverse birth outcomes, as well as outcomes following vaccination during early pregnancy. STRENGTHS AND LIMITATIONS: Strengths of this study include the inclusion of comprehensive population-level vaccine registry data in combination with a validated, allinclusive delivery database including births at multiple community and teaching hospitals across two states. As the data were extracted from the primary medical record it is not subject to recall bias. Given the absence of infection in any vaccinated patients after the first dose administration (incidence rate ratio of zero and vaccine efficacy of one) with a short observation period, our ability to estimate vaccine efficacy is limited for this cohort. Other limitations of this analysis include the small percentage of non-white subjects in this geographic region, the potential for confounding due to the observational nature of the study, as well as the data currently available being biased toward those vaccinated later in gestation and skewed toward the population in the United States healthcare workforce. Finally, only two COVID-19 infections occurred in the vaccinated group early in pregnancy, so they may be a group who had lower baseline exposure compared to the unvaccinated group. Pre-pregnancy COVID-19 infection history was not available, so previously existing antibody status was unknown and limits the efficacy conclusions.

CONCLUSIONS: While COVID-19 infection in pregnancy has been associated with significant adverse maternal and neonatal outcomes in multiple studies, the current findings should give clinicians confidence that COVID-19 vaccination during pregnancy is protective against maternal SARS-CoV-2 infection and that no pattern of adverse maternal or birth outcomes is evident after vaccination during pregnancy. Outreach to under-represented populations of pregnant patients should be a focus of future education and vaccination efforts. Stillbirth 6 (0.3%) 0 (0.0%) 6 (0.3%) 1.00 Abbreviations: AOI, Adverse Outcome Index; IQR, interquartile range (25th and 75th percentiles) 1 Thromboembolism and stroke were assessed within 4 weeks before or after delivery. Crude percentages are reported among the subset who either had the outcome or who had sufficient followup. †Comparisons between groups were evaluated using the Wilcoxon rank sum test for gestation age and length of stay and the chi-square test or Fisher's exact test for the categorical variables. ‡ Length of stay from time of delivery to discharge from the hospital.

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19

COVID-19 Vaccination in Pregnant and Lactating Women

Vaccinating Pregnant and Lactating Patients Against COVID-19Practice Advisory: American College of Obstetrics and Gynecology

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study

Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study

Pregnancy, Postpartum Care, and COVID-19 Vaccination in 2021

Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

The Adverse Outcome Index: Putting Quality into an Outcome Measure

Accuracy of the adverse outcome index: An obstetrical quality measure

Impact of a labor and delivery safety bundle on a modified adverse outcomes index Presented at the Central Association of Obstetricians and Gynecologists 82nd annual meeting

This work was funded in part by grant FP00085005-A1-03-S14 from the U.S. National Center for Translational Sciences. The funder did not participate in the study design, data collection, data analysis, or writing for publication.